within Pharmacolibrary.Drugs.ATC.G;

model G03AA14
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.63,
    Cl             = 0.43333333333333335,
    adminDuration  = 600,
    adminMass      = 0.0025,
    adminCount     = 1,
    Vd             = 1.24,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.009166666666666667,
    Tlag           = 10.020000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Nomegestrol acetate with estradiol is a combined oral contraceptive used for female contraception. It combines nomegestrol, a progestogen, with estradiol, a naturally occurring estrogen. This combination is approved and marketed in several countries for regular use in birth control.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adult females following oral administration. No direct published population PK models or detailed compartmental parameters for the combination product found.</p><h4>References</h4><ol><li>Stefano Lello,Nomegestrol acetate: pharmacology, safety profile and therapeutic efficacy.,Drugs,2010<a href='https://pubmed.ncbi.nlm.nih.gov/20329803/'>https://pubmed.ncbi.nlm.nih.gov/20329803/</a></li><li>Teun M Post, Mireille Gerrits, Thomas Kerbusch, Rik de Greef,Prediction of nomegestrol acetate pharmacokinetics in healthy female adolescents and adults by whole-body physiology-based pharmacokinetic modelling and clinical validation.,Contraception,2016<a href='https://pubmed.ncbi.nlm.nih.gov/26365792/'>https://pubmed.ncbi.nlm.nih.gov/26365792/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end G03AA14;
